Jacob D. Cohen

Jacob D. Cohen

Auto-generated profile, based on publicly available information

Jacob D. Cohen

Interdisciplinary Biological Sciences Graduate Program

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in FEMS Microbiology Reviews
Verified
Journal Article
Open access
PDF file
MPMilankumar Patel
Milankumar Patel
FSFarah Shahjin
Farah Shahjin
JCJacob D Cohen
Jacob D Cohen
MHMahmudul Hasan
Mahmudul Hasan
JMJatinkumar Machhi
Jatinkumar Machhi
HGHoward Eliot Gendelman
Howard Eliot Gendelman
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to coronavirus disease 2019 (COVID-19). Virus-specific immunity controls infection, transmission and disease severity. With respect to disease severity, a spectrum of clinical outcomes occur associated with age, genetics, comorbidities and immune responses in an infected person. Dysfunctions in innate and adaptive immunity commonly follow viral infection. These are heralded by altered innate mononuclear phagocyte differentiation, activation, intracellular killing and adaptive memory, effector, and regulatory T cell responses. All of such affect viral clearance and the progression of end-organ disease. Failures to produce effective controlled antiviral immunity leads to life-threatening end-organ disease that is typified by the acute respiratory distress syndrome. The most effective means to contain SARS-CoV-2 infection is by vaccination. While an arsenal of immunomodulators were developed for control of viral infection and subsequent COVID-19 disease, further research is required to enable therapeutic implementation.


14 January 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JHJonathan Herskovitz
Jonathan Herskovitz
MHMahmudul Hasan
Mahmudul Hasan
MPMilankumar Patel
Milankumar Patel
WBWilson R. Blomberg
Wilson R. Blomberg
JCJacob D. Cohen
Jacob D. Cohen
HGHoward Eliot Gendelman
Howard Eliot Gendelman
A barrier to HIV-1 cure rests in the persistence of proviral DNA in infected CD4+ leukocytes. The high mutation rate of HIV-1 gives rise to numerous circulating strains with increased capacity for immune evasion and antiretroviral drug resistance. To facilitate viral elimination while accounting for this diversity, we propose genetic inactivation of proviral DNA with CRISPR-spCas9. We designed a library of “mosaic gRNAs” against a HIV-1 consensus sequence constructed from 4004 clinical strains, targeting the viral transcriptional regulator tat. Testing in 7 HIV-1 transmitted founder strains led, on average, to viral reductions of 82% with tandem TatD and TatE (TatDE) treatment. No off-target cleavages were recorded. Lentiviral transduction of TatDE attenuated latency reversal by 94% in HIV-infected, transcriptionally silent ACH2 T cells. In all, TatDE guide RNAs successfully disrupted 5 separate HIV-1 exons ( tat 1-2 / rev 1-2 / gp41 ) providing a pathway for CRISPR-directed HIV-1 cure therapies. Significance Statement: Over 38 million individuals worldwide are infected with HIV-1, which necessitates lifelong dependence on antiretroviral therapy (ART) to prevent viral replication that leads to AIDS. Efforts to rid hosts of HIV-1 are limited by the virus’ abilities to integrate proviral DNA in nuclei, mutate their genomes, and lay dormant for decades during ART treatment. We developed mosaic guide RNAs, TatD and TatE, for CRISPR-Cas9 that recognize the majority of known HIV-1 strains and inactivate 94% of proviral DNA in latently infected cells. Tandem TatDE-CRISPR inactivation of 5 viral exons (t at 1-2 , rev 1-2 , and gp41 ), which blocked HIV-1 replication for 28 days in CD4+ T cells without unwanted editing to the host genome, may serve as a viable strategy for HIV cure.